However, in P10, diabetes remained poorly controlled and because of low serum leptin levels (5.1 μg/L; reference >12 μg/L), recombinant human metraleptin therapy was started with good effect on glucose regulation, hepatic steatosis, and albuminuria. The gene discussed is LEP; the disease is fatty liver disease.